Poxel names industry veteran as CSO

24 January 2020

Late Thursday, French metabolic diseases biotech company Poxel (Euronext: POXEL) announced the appointment of pharma industry veteran David Moller as chief scientific officer (CSO).

Dr Moller will be responsible for leading scientific-related activities to support the advancement of the company, including scientific innovation and scientific communications at Poxel. He will be based in Boston, further expanding Poxel’s presence in the USA.

Dr Moller will join the executive management team and work closely with the R&D team in France, including Sébastien Bolze, who has been appointed to the newly-created position of chief operating officer, executive vice president, non-clinical and manufacturing operations. In this new role, Dr Bolze will oversee and coordinate R&D operations.

Previous executive positions at Sigilon, Lilly and Merck

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK